Interleukin-6 (IL-6) is a cytokine involved in different physiologic and pathophysiologic processes including carcinogenesis.
Variants
variants in susceptibility to systemic-onset juvenile rheumatoid arthritis (MIM.604302)
In 2003, a single nucleotide polymorphism (-174G/C) of the IL-6 gene promoter has been linked to breast cancer prognosis in node-positive (N+) breast cancer patients. Since, different studies have led to conflicting conclusions about its role as a prognostic and/or diagnostic marker. No association or trend of association between -174G/C polymorphism of IL-6 gene promoter gene and breast cancer diagnosis or prognosis was shown, even in meta-analyses.
Reviews
Naugler WE, Karin M. The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008 Mar;14(3):109-19. PMID: 18261959
References
Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer. Chérel M, Campion L, Bézieau S, Campone M, Charrier J, Gaschet J, Ricolleau G, Gouraud W, Charbonnel C, Jézéquel P. Cytokine. 2009 Sep;47(3):214-23. PMID: 19640729